INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim welcomes the international evidence-based 2015 ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis – An Update of the 2011 Guideline which suggests that clinicians use OFEV® (nintedanib*) in patients with IPF***.1 The committee noted the high value of OFEV® on patient-important outcomes such as disease progression as measured by rate of forced vital capacity (FVC) decline and mortality. The recommenda
| < Prev | Next > |
|---|
